Эффективность тройной комбинации в терапии распространенной меланомы

Abstract

Skin melanoma is one of the most aggressive malignant forms of neoplasms, difficult to treat, has a high potential for growth and dissemination, as well as regional and widespread metastasis. Over the past few years, the issues of efficacy and safety of a number of drugs used to treat patients both in mono mode and in combination therapy regimens have been actively discussed. One notable study on the efficacy of a new drug combination is IMspire150. The use of a triple combination (atezolizumab, vemurafenib, cobimetinib) in the first line of therapy for advanced melanoma with a positive BRAF V600 mutation is presented in this clinical case.